NFKB activating protein (NKAP)

NFKB activating protein (NKAP) is a chromatin-associated nuclear protein that acts as a transcriptional corepressor and regulator of gene expression. It is involved in activation of the NF-kappaB (NF-κB) signaling pathway, particularly in response to TNF and IL-1. In addition, NKAP acts as a transcriptional repressor of Notch target genes by associating with the histone deacetylase HDAC3 and the Notch corepressor complex. NKAP is essential for alphabeta T cell development and thus plays a crucial role in immune system regulation. Mutations in NKAP have been linked to certain intellectual disability syndromes (e.g., X-linked, syndromic, Hackmann-Di Donato type) as well as scoliosis. NKAP functions through chromatin binding and interaction with various protein complexes, but is not a classical receptor, enzyme, or transporter[1].\n\nNKAP is not currently the target of any approved drugs or drug candidates, nor are there established biomarkers or specific therapeutic safety concerns associated with it based on current knowledge[1].\n\nKey points:\n- Canonical function: transcriptional corepressor, chromatin binding, NF-kappaB activation, Notch signaling repression\n- Disease associations: syndromic intellectual disability, scoliosis\n- Molecular family: does not fall under classical families (e.g., receptor, kinase, ion channel), but often functionally grouped with transcription regulators and chromatin modulators\n- No established drugs, biomarkers, or clinical safety data as of current understanding\n\nReferences: GeneCards/UniProtKB/OMIM for NKAP[1]

Other names

NF-kappa-B-activating proteinFLJ22626NF kappaB activating proteinMRXSHDNKAP